With increased understanding of the aforementioned factors and the potential molecular mechanisms involved in GC, we designed a series of in vivo and in vitro experiments aimed at investigating the underlying relationships of UCA1, PRL-3, and miR-495 in GC cells in hopes of uncovering a novel therapeutic target in the treatment of GC. This evidence concerns the gene PTP4A3 and gastric cancer.